Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice

被引：2
|
作者：
Grassi, Paolo [1 ]
Verzoni, Elena [1 ]
Mennitto, Alessia [1 ]
Procopio, Giuseppe [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Genitourinary Canc Unit, Via G Venezian 1, I-20133 Milan, Italy
来源：
TRANSLATIONAL ANDROLOGY AND UROLOGY | 2016年 / 5卷 / 06期
关键词：
PHASE-3; TRIAL; OPEN-LABEL; EVEROLIMUS; NIVOLUMAB;
D O I：
10.21037/tau.2016.11.06
中图分类号：
R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
摘要：
引用
收藏
页码：974 / 976
页数：3
相关论文
共 50 条
  • [21] Regional Differences in the Phase III Meteor Study of Cabozantinib (CABO) Versus Everolimus (EVE) in Advanced Renal Cell Carcinoma (RCC)
    Mainwaring, Paul
    Tannir, Nizar M.
    Powles, Thomas
    Motzer, Robert J.
    Rolland, Frederic
    Gravis, Gwanaelle
    Staehler, Michael
    Rink, Michael
    Retz, Margitta
    Csoszi, Tibor
    McCaffrey, John A.
    De Giorgi, Ugo
    Caserta, Claudia
    Cheporov, Sergey
    Gonzalez, Emilio Esteban
    Duran, Ignacio
    Larkin, James G.
    Berg, William
    Clary, Douglas O.
    Escudier, Bernard
    Choueiri, Toni K.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 129 - 130
  • [22] Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study
    Bracarda, S.
    Choueiri, T. K.
    Powles, T.
    Motzer, R. J.
    Olencki, T.
    Frontera, O. A.
    Oudard, S.
    Rolland, F.
    Tomczak, P.
    Castellano, D.
    Appleman, L.
    Drabkin, H.
    Vaena, D.
    Milwee, S.
    Youkstetter, J.
    Escudier, B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 72 : S196 - S196
  • [23] METEOR: results from the randomized phase 3 trial of cabozantinib versus everolimus in pts with advanced renal cell carcinoma (RCC)
    Powles, Thomas
    Escudier, Bernard
    Mainwaring, Paul N.
    Rini, Brian I.
    Donskov, Frede
    Hammers, Hans J.
    Hutson, Thomas E.
    Roth, Bruce
    Peltola, Katriina
    Lee, Jae Lyun
    Heng, Daniel Y. C.
    Schmidinger, Manuela
    Borgman, Anne
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Tannir, Nizar M.
    Motzer, Robert J.
    Choueiri, Toni K.
    [J]. BJU INTERNATIONAL, 2015, 116 : 19 - 19
  • [24] NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma
    Elsada, Ahmed
    Adler, Amanda I.
    [J]. LANCET ONCOLOGY, 2017, 18 (09): : 1153 - 1154
  • [25] An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC)
    D'Angelo, Alberto
    Bagby, Stefan
    Di Pierro, Giulia
    Chirra, Martina
    Nobili, Stefania
    Mini, Enrico
    Villari, Donata
    Roviello, Giandomenico
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 149
  • [26] Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial
    Denize, Thomas
    Farah, Subrina
    Cimadamore, Alessia
    Flaifel, Abdallah
    Walton, Emily
    Sticco-Ivins, Maura A.
    Labaki, Chris
    Braun, David A.
    Sun, Maxine
    Wang, Evelyn
    Xie, Wanling
    Choueiri, Toni K.
    Signoretti, Sabina
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (04) : 748 - 755
  • [27] Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
    Thomas Powles
    Toni K. Choueiri
    Robert J. Motzer
    Eric Jonasch
    Sumanta Pal
    Nizar M. Tannir
    Sabina Signoretti
    Rajesh Kaldate
    Christian Scheffold
    Evelyn Wang
    Dana T. Aftab
    Bernard Escudier
    Daniel J. George
    [J]. BMC Cancer, 21
  • [28] Overall Survival (OS) in Meteor, A Randomised Phase III Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma (RCC)
    Mainwaring, Paul
    Powles, Thomas
    Escudier, Bernard J.
    Tannir, Nizar M.
    Rini, Brian I.
    Hammers, Hans J.
    Donskov, Frede
    Roth, Bruce J.
    Peltola, Katriina
    Lee, Jae-Lyun
    Heng, Daniel Yick Chin
    Schmidinger, Manuela
    Aftab, Dana T.
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Pal, Sumanta K.
    Hutson, Thomas E.
    Motzer, Robert J.
    Choueiri, Toni K.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 109 - 109
  • [29] Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)
    Tannir, N.
    Powles, T.
    Motzer, R. J.
    Rolland, F.
    Gravis, G.
    Staehler, M.
    Rink, M.
    Retz, M.
    Csoszi, T.
    McCaffrey, J.
    De Giorgi, U.
    Caserta, C.
    Cheporov, S.
    Esteban Gonzalez, E.
    Duran, I.
    Larkin, J. G.
    Berg, W.
    Clary, D.
    Escudier, B.
    Choueiri, T. K.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [30] Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).
    Escudier, Bernard J.
    Motzer, Robert J.
    Powles, Thomas
    Tannir, Nizar M.
    Davis, Ian D.
    Donskov, Frede
    Grunwald, Viktor
    Heng, Daniel Yick Chin
    Hutson, Thomas
    Melichar, Bohuslav
    Nosov, Dimitry
    Rini, Brian I.
    Salman, Pamela
    Sternberg, Cora N.
    Szczylik, Cezary
    Wolter, Pascal
    Arroyo, Alan M.
    Mangeshkar, Milan
    Agarwal, Neeraj
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345